Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 5:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Dermatitis, Atopic
Interventions: Abrocitinib 100 mg, Abrocitinib 200 mg, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 3,166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 156
States / cities: Birmingham, Alabama • Anaheim, California • Encinitas, California + 101 more

Conditions: Aortic Valve Stenosis, Aortic Valve Stenosis With Insufficiency, Regurgitation, Aortic Valve, Aortic Valve Incompetence
Interventions: EDWARDS INTUITY valve; Device
Lead sponsor: Edwards Lifesciences; Industry
Eligibility: 18 Years and older
Enrollment: 934 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 29
States / cities: Los Angeles, California • Newport Beach, California • Palo Alto, California + 24 more

Conditions: Atopic Dermatitis
Interventions: MM36 topical ointment, 1%; Drug
Lead sponsor: Medimetriks Pharmaceuticals, Inc; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 10
States / cities: Fremont, California • Irvine, California • San Diego, California + 7 more

Conditions: Cardiovascular Diseases
Interventions: Traditional Cardiac Rehabilitation, Intensive Cardiac Rehabilitation, C2life® Food; Behavioral · Other
Lead sponsor: Pritikin ICR; Other
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Ypsilanti, Michigan • Asheville, North Carolina • Kingsport, Tennessee

Conditions: Cystic Fibrosis
Interventions: N-acetylcysteine (NAC), Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 7 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 11
States / cities: Birmingham, Alabama • Stanford, California • Denver, Colorado + 8 more

Conditions: Degenerative Osteoarthritis
Interventions: TG-C, Placebo Control; Biological
Lead sponsor: Kolon TissueGene, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 531 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 27
States / cities: Tucson, Arizona • Anaheim, California • Beverly Hills, California + 23 more

Conditions: Dry Eye Disease (DED)
Interventions: Active Comparator EBI-005, Placebo Comparator; Drug
Lead sponsor: Eleven Biotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 670 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 45
States / cities: Chandler, Arizona • Mesa, Arizona • Little Rock, Arkansas + 38 more

Conditions: Healthy
Interventions: Schedule A, Schedule B, Schedule C, Schedule D, Schedule E; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2011
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Postoperative Care, Postoperative Complications, Cognition, Nutritional Assessment, Nutritional Intervention
Interventions: Nutritional Shake, Nutritional Instructions Only; Dietary Supplement · Other
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 70 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Fibromyalgia
Interventions: [S,S]-Reboxetine, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 136
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tallassee, Alabama + 111 more

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Dex-methylphenidate hydrochloride extended-release (Focalin XR), Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 5
States / cities: Little Rock, Arkansas • Winter Park, Florida • Las Vegas, Nevada + 2 more

Conditions: Dental Caries
Interventions: 0.24% Sodium Fluoride Dentifrice, 1.5% Arginine Dentifrice, 4.0% Arginine Dentifrice, 8.0% Arginine Dentifrice; Drug
Lead sponsor: Colgate Palmolive; Industry
Eligibility: 10 Years to 14 Years
Enrollment: 2,025 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 8
States / cities: Loma Linda, California • Gainesville, Florida • Indianapolis, Indiana + 4 more

Conditions: Ovarian Cancer, Endometrial Cancer
Interventions: Tc 99m EC20; Drug
Lead sponsor: Endocyte; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Angelman Syndrome
Interventions: MVX-220; Genetic
Lead sponsor: MavriX Bio, LLC; Industry
Eligibility: 4 Years to 50 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 3
States / cities: Los Angeles, California • Chicago, Illinois • Boston, Massachusetts

Conditions: Atrial Fibrillation - Symptomatic
Interventions: Radiofrequency ablation; Procedure
Lead sponsor: Ohad Ziv; Other
Eligibility: 18 Years to 85 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: LPL Deficiency
Interventions: alipogene tiparvovec, Prednisolone, Cyclosporins, Mycophenolate mofetil; Drug
Lead sponsor: UniQure Biopharma B.V.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypertension
Interventions: amlodipine besylate/benazepril hydrochloride; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 259 participants
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Presbyopia
Interventions: CSF-1, Vehicle; Drug
Lead sponsor: Orasis Pharmaceuticals Ltd.; Industry
Eligibility: 45 Years to 64 Years
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 18
States / cities: Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 15 more

Conditions: Coronary Artery Disease (CAD)
Interventions: AI-ECG Analysis; Device
Lead sponsor: Heart Input Output Inc; Industry
Eligibility: 18 Years to 89 Years
Enrollment: 978 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Houston, Texas

Conditions: Asthma
Interventions: GSK3511294, Placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 41
States / cities: Alabaster, Alabama • Mobile, Alabama • Phoenix, Arizona + 34 more

Conditions: Chronic Pruritus of Unknown Origin
Interventions: Remibrutinib, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 8
States / cities: Miami, Florida • Savannah, Georgia • Indianapolis, Indiana + 5 more

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: OTX-TIC low dose Travoprost Intracameral Implant, OTX-TIC high dose Travoprost Intracameral Implant, Durysta, Bimatoprost Intracameral Implant 10 µg; Drug
Lead sponsor: Ocular Therapeutix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 30
States / cities: Dothan, Alabama • Huntington Beach, California • Irvine, California + 27 more

Conditions: Diabetes Mellitus, Type 2
Interventions: TT223 with Metformin and/or TZD, Placebo with Metformin and/or TZD; Drug
Lead sponsor: OPKO Health, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 20
States / cities: Artesia, California • Los Angeles, California • Santa Ana, California + 17 more

Conditions: Advanced Solid Tumours, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC)
Interventions: AZD0022, Cetuximab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Duarte, California • New York, New York • Fairfax, Virginia

Search by objective public record fields.

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

Surgical Treatment of Aortic Stenosis With a Next Generation, Rapid Deployment Surgical Aortic Valve

Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis

Multi-Center Study of Clinical and Inflammatory Outcomes in Intensive Cardiac Rehabilitation and Traditional Cardiac Rehabilitation Programs

NAC Phase IIB: A Multi-Center, Phase IIB, Randomized, Placebo-controlled, Double-Blind Study Of The Effects Of N-Acetylcysteine On Redox Changes and Lung Inflammation In Cystic Fibrosis Patients

Study to Determine the Efficacy and Safety of TG-C in Subjects With Kellgren/Lawrence Grade 2 or 3 OA of the Knee

Phase 3 Study of EBI-005 in Dry Eye Disease

A Study to Determine the Pharmacodynamics of LX4211 Relative to Meals in Healthy Subjects

Nutrition to Support Postoperative Recovery

A 14-week, Multi-center Study of [S,S]-Reboxetine in Patients With Fibromyalgia.

A Study of Dex-methylphenidate Extended Release in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD)

A Clinical Trial to Assess the Safety and the Anti-caries Efficacy of COL 101 (Arginine) Non-fluoride Dentifrices in Comparison With 0.24% Sodium Fluoride (1100 Ppm F) Dentifrice Control in 10 to 14-year-old Children

Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Women With Suspected Ovarian or Endometrial Cancer

A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome

Low Voltage-Directed Catheter Ablation for Atrial Fibrillation

Alipogene Tiparvovec for the Treatment of LPLD Patients

Study Comparing the Efficacy of Amlodipine Besylate/Benazepril Versus Amlodipine in the Treatment of Severe Hypertension

An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-2)

Analysis of ECGio to Predict Coronary Stenosis Against a Mixed Reference Standard

A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)

A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)

A Trial of TT223 in Patients With Type 2 Diabetes Who Are Taking Metformin and/or Thiazolidinedione

A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation